TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1.1 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE

1.1.2 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION

1.1.3 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER

1.1.4 GLOBAL PLASMA FRACTIONATION MARKET, BY REGION

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 SCOPE OF THE STUDY

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 RESEARCH PROCESS

3.2 PRIMARY RESEARCH

3.3 SECONDARY RESEARCH

3.4 MARKET SIZE ESTIMATION

3.5 TOP DOWN & BOTTOM-UP APPROACH

3.6 FORECAST MODEL

3.7 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS

4.1 DRIVERS

4.1.1 GROWING USE OF IMMUNOGLOBULINS FOR VARIOUS THERAPEUTIC AREA

4.1.2 DEMAND FOR PLASMA DERIVED MEDICINAL PRODUCTS DRIVES THE MARKET GROWTH

4.1.3 DRIVER IMPACT ANALYSIS

4.2 RESTRAINTS

4.2.1 EMERGENCE OF RECOMBINANT THERAPIES AS AN ALTERNATIVE TO PLASMA DERIVED MEDICINES RESTRAINTS THE MARKET GROWTH

4.2.2 RESTRAINT IMPACT ANALYSIS

4.3 OPPORTUNITIES

4.3.1 LAUNCH OF NEW TECHNOLOGIES BY KEY PLAYERS TO AUGMENT MARKET GROWTH

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS

5.1.1 RAW APPLICATIONS

5.1.2 MANUFACTURES

5.1.3 DISTRIBUTION

5.1.4 END USER

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 MAJOR COLD CHAIN PRODUCTS/DEVICES IN THE PLASMA FRACTIONATION MARKET

5.4 IMPACT OF COVID-19 ON THE GLOBAL PLASMA FRACTIONATION MARKET

5.4.1 IMPACT ON SUPPLY CHAIN

5.4.2 IMPACT ON PRODUCTION

5.4.3 IMPACT ON REGIONS

5.4.4 IMPACT ON DEMAND-SUPPLY GAP ANALYSIS

5.4.5 IMPACT ON PRICING

6 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE

6.1 OVERVIEW

6.2 IMMUNOGLOBULIN

6.2.1 Intravenous Immunoglobulins

6.2.2 Subcutaneous Immunoglobulins

6.2.3 Others

6.3 COAGULATION FACTOR CONCENTRATES

6.3.1 Factor VIII

6.3.2 Factor IX

6.3.3 Von Willebrand Factor

6.3.4 Prothrombin Complex Concentrate

6.3.5 Fibrinogen Concentrates

6.3.6 Factor XIII

6.4 ALBUMIN

6.5 PROTEASE INHIBITORS

6.6 OTHERS

7 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 IMMUNOLOGY

7.3 NEUROLOGY

7.4 HEMATOLOGY

7.5 CRITICAL CARE

7.6 PULMONOLOGY

7.7 RHEUMATOLOGY

7.8 HEMATO-ONCOLOGY

7.9 OTHERS

8 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS & CLINICS

8.3 CLINICAL RESEARCH LABORATORIES

8.4 ACADEMIC INSTITUTES

8.5 OTHERS

9 GLOBAL PLASMA FRACTIONATION, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 ITALY

9.3.4 SPAIN

9.3.5 UK

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 CHINA

9.4.2 JAPAN

9.4.3 INDIA

9.4.4 AUSTRALIA

9.4.5 SOUTH KOREA

9.4.6 REST OF ASIA PACIFIC

9.5 REST OF THE WORLD

9.5.1 LATIN AMERICA

9.5.2 MIDDLE EAST

9.5.3 AFRICA

10 COMPETITIVE LANDSCAPE

10.1 COMPETITIVE OVERVIEW

10.2 MAJOR GROWTH STRATEGY IN THE GLOBAL PLASMA FRACTIONATION MARKET

10.3 COMPETITIVE BENCHMARKING

11 COMPANY PROFILES

11.1 CSL BEHRING

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 GRIFOLS THERAPEUTICS

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 BAXTER INTERNATIONAL INC.

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 MITSUBISHI TANABE

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 TAKEDA PHARMACEUTICAL

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 OCTAPHARMA AG

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 HUALAN BIO

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.8 KEDRION S.P.A

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.9 LFB GROUP

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.10 BIOTEST AG

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 SWOT ANALYSIS

11.10.6 KEY STRATEGIES